A proposal for a biomedical imaging beamline at MAX IV
Biomedical imaging is used in three main contexts; diagnosis, guiding therapy, and basic studies of the origin and manifestations of disease. The present-day clinical imaging methods have limitations due to insufficient spatial and/or temporal resolution or weak interaction between the probe and organ. Current X-ray methods are based on tissue-specific differences in attenuation, which can be enhanced by contrast agents, but in many cases low contrast or excessive radiation dose limit the applications. The high intensity, monochromatization, energy tunability and coherence of synchrotron radiation beams, coupled with advanced x-ray optics and new detector technology, has lead to methods that have revolutionized x-ray imaging of tissues and organs in pre-clinical research. Future development in these areas will continue to have great impact. The goal is to gain new knowledge and develop techniques that can be translated into clinical medicine. Modern techniques of analyzer based Imaging (ABI), propagation phase contrast imaging (PPI), grating interferometry (GI), dark-field imaging, and K-edge subtraction (KES) will all take advantage of the high brightness of MedMAX. The anticipated user community will use MedMAX for in vivo imaging of small animals in applications for physiological and morphological characterization of organs, as well as for micro-localization of toxic elements and tumour-targeting molecules in tissue samples.
The opportunities presented by MedMAX are widely recognized, and experienced synchrotron research groups from the Nordic countries will form the core of an advanced biomedical user community right from the start. Some particularly interesting research examples involving members of the proposal team are given in the following.